Compare Amphastar Pharmaceuticals Inc (AMPH) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Chipotle Mexican Grill, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Chipotle Mexican Grill, Inc. trades at $35.35 (market cap $45.22B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 54.7× Amphastar Pharmaceuticals Inc's market cap, and Chipotle Mexican Grill, Inc. is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | CMG | |
|---|---|---|
Market Cap | $826.08M | $45.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $56.00 |
52-Week Low | $16.87 | $28.17 |
Enterprise Value | $1.22B | $49.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Chipotle Mexican Grill (CMG) trades at $35.25, up 1.88% on the day, with strong analyst support and consistent earnings beats. The stock shows bullish technical signals with support at $34 and resistance at $35. Revenue grew to $11.93 billion in 2025, with a net income margin of 11.96%, though margins have narrowed slightly from prior years. Recent news highlights operational focus and menu innovation as growth drivers.
Outlook remains positive with a $40.46 consensus price target, but risks include cost pressures and competitive threats. The stock offers growth potential through expansion and operational excellence, yet investors should monitor margin trends and consumer spending shifts in the volatile restaurant sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
